The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
Karen Legler(Christian-Albrechts-Universität zu Kiel), Anna Trauzold(Christian-Albrechts-Universität zu Kiel)
Cited by 40
Related Papers
Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells
|PLoS ONE|2019|50
TRAIL-receptor 2—a novel negative regulator of p53
|Cell Death and Disease|2021|19
Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasis
|Frontiers in Oncology|2023|10
Endogenous TRAIL-R4 critically impacts apoptotic and non-apoptotic TRAIL-induced signaling in cancer cells
|Frontiers in Cell and Developmental Biology|2022|4